Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins

Inclusion Criteria: * Age ≥18 years * On haemodialysis at a frequency of 3 sessions of 4 hours per week, for at least 3 months. * For patients of childbearing age, effective contraception (sexual abstinence, hormonal contraception, intrauterine device or hormone-releasing system, cap, diaphragm or sponge with spermicide, condom) for the entire duration of treatment is required. A blood pregnancy test (beta-human chorionic gonadotropin (HCG)) will be carried out at inclusion. * Patient affiliated to a social security scheme * Free, informed and written consent signed by the patient Exclusion Criteria: * Residual diuresis \> 100 mL per day * Pregnant or breast-feeding * Uncontrolled hypertension \> 180/115 millimetre of mercury (mmHg) * Perdialytic hypotension requiring vascular filling \> 100 mL during the last 3 sessions * Patients already on parenteral nutrition * Patients already on Vitamin K antagonists (VKA) (or prescribed less than one month before inclusion) * Patients with allergy to heparin or requiring haemodialysis without anticoagulant (recent haemorrhage) * Criteria relating to products/procedures: Patient with * an allergy to egg, soya or peanut proteins or to one of the active ingredients or one of the excipients (glycerol, egg phospholipids for injection, a-tocopherol, sodium oleate (to adjust the pH), water for injection) of Médialipide * Severe hyperlipidaemia or severe lipid metabolism disorder characterised by hypertriglyceridaemia \> 3 mmol/l * S…